News - Victoza

Filter

Current filters:

Victoza

Popular Filters

10 to 34 of 38 results

Data on Novo Nordisk's Victoza further supporting safety presented at expert workshop

14-06-2013

Danish Insulin giant Novo Nordisk (NOV: N) presented data further supporting the safety of Victoza (liraglutide…

DiabetesNovo NordiskPharmaceuticalResearchVictoza

Novo Nordisk files Tresiba/Victoza combo IDegLira for EU approval

31-05-2013

Danish insulin giant Novo Nordisk (NOV: N) said today (May 31) that it has submitted a marketing authorization…

DiabetesEuropeIDegLiraNovo NordiskPharmaceuticalRegulationTresibaVictoza

Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial

24-05-2013

Danish insulin giant Novo Nordisk (NOV: N) has released headline results from a 56-week double-blind…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearchVictoza

New study shows Novo Nordisk's Victoza achieves 6% weight loss in type 2 diabetes patients

18-03-2013

Danish insulin giant Novo Nordisk (NOVN: N) has released headline results from a 56-week, double-blind…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearchVictoza

Positive new Ph III data on Novo Nordisk's Victoza

28-11-2012

Global Denmark-based insulin giant Novo Nordisk (NOV: N) yesterday reported data from two Phase IIIb…

DiabetesNovo NordiskPharmaceuticalResearchVictoza

Zealand Pharma valuation hinged on Lyxi/Lanti "fixflex"

23-11-2012

The recent European Medicine Agency advisory committee, CHMP, positive opinion for French drug major…

BiotechnologyDiabetesFinancialLantusLyxumiaNovo NordiskRegulationResearchSanofiTresibaVictozaZealand Pharma

Head-to-head trial of diabetes drugs Victoza and Bydureon yields mixed results

08-11-2012

A direct, head-to-head comparison of two of the newer treatments available for type 2 diabetes yielded…

AmylinBydureonDiabetesEli LillyNovo NordiskPharmaceuticalResearchVictoza

South Korea's type 2 diabetes drug market to grow to over $550 million in 2016

23-10-2012

The type 2 diabetes therapeutic market in South Korea will grow 11% annually from $330 million in 2011…

AmylinAsia-PacificBydureonDiabetesJanumetJanuviaMarkets & MarketingMerck & CoNovo NordiskPharmaceuticalVictoza

Highlights of American Diabetes Association meeting

11-06-2012

The weekend saw a flood of new data on diabetes drug candidates and currently approved treatments presented…

Boehringer IngelheimDegludecDiabetesEli LillyempagliflozinLyxumiaNovo NordiskPharmaceuticalResearchSanofiTradjentaVictoza

Positive Ph III results for Novo Nordisk's degludec; US advocacy calls for Victoza's withdrawal

23-04-2012

Danish diabetes specialist Novo Nordisk (NOV: N) says that its investigational ultra-long-acting insulin…

DegludecDiabetesNorth AmericaNovo NordiskPharmaceuticalRegulationResearchVictoza

Victoza US label update includes superior efficacy over Januvia, says Novo Nordisk

10-04-2012

The US Food and Drug Administration has approved an update to the product label for Victoza (liraglutide…

DiabetesJanuviaLevemirMerck & CoNorth AmericaNovo NordiskPharmaceuticalRegulationResearchVictoza

Victoza sales boost Novo Nordisk

03-02-2012

Danish insulin giant Novo Nordisk (NVO: N) yesterday reported full-year 2011 sales of 66.35 billion Danish…

DiabetesFinancialNovo NordiskPharmaceuticalVictoza

GlaxoSmithKline’s albiglutide fails to show superiority over Novo Nordisk’s Victoza

18-11-2011

UK pharma giant GlaxoSmithKline (LSE: GSK) released disappointing top-line results from the first of…

albiglutideDiabetesGlaxoSmithKlineNovo NordiskPharmaceuticalResearchVictoza

EU OKs two new indications for Novo Nordisk’s Levemir

03-11-2011

There was good news for Danish insulin giant Novo Nordisk (NVO: N) yesterday, when the European Commission…

DiabetesEuropeLevemirNovo NordiskPharmaceuticalRegulationVictoza

Strong new data on Novo Nordisk’s Victoza and Lilly/Amylin’s Bydureon presented at EADS

13-09-2011

A significantly higher proportion of patients reached the target for blood sugar control (HbA1c target…

AlkermesAmylinBydureonDiabetesEli LillyNovo NordiskPharmaceuticalResearchVictoza

Novo Nordisk first-half 2011 sales and profit leap

04-08-2011

Danish insulin giant Novo Nordisk (NVO: N) posted first-half 2011 sales of 31.69 billion Danish kroner…

DiabetesFinancialNovo NordiskPharmaceuticalVictoza

10 to 34 of 38 results

Back to top